Статті в журналах: "Compound Kushen Injection"

1

Huang, Zhihong, and Ping Wei. "Compound Kushen Injection for gastric cancer." Medicine 98, no. 45 (November 2019): e17927. http://dx.doi.org/10.1097/md.0000000000017927.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Yang, Xinwei, Xiyun Zhao, and Xiaoxia Wang. "Compound kushen injection for multiple myeloma." Medicine 98, no. 50 (December 2019): e18257. http://dx.doi.org/10.1097/md.0000000000018257.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Guo, Yu-ming, Yi-xue Huang, Hong-hui Shen, Xiu-xiu Sang, Xiao Ma, Yan-ling Zhao, and Xiao-he Xiao. "Efficacy of Compound Kushen Injection in Relieving Cancer-Related Pain: A Systematic Review and Meta-Analysis." Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/840742.

Повний текст джерела

Анотація:

Despite widespread popular use of complementary and alternative medicine (CAM) therapies, a rigorous evidence based on the efficacy of compound kushen injection (CKI) for cancer-related pain is lacking. In this study, we evaluated the efficacy and safety of compound kushen injection and provided information for current or future research and clinical application. Sixteen trials were identified with a total of 1564 patients. The total pain relief rate of CKI plus chemotherapy is better than chemotherapy except for colorectal cancer. The treatment groups achieved a reduction in the incidences of leukopenia and gastrointestinal, hepatic, and renal functional lesion. However, there is paucity of multi-institutional RCTs evaluating compound kushen injection for cancer pain with adequate power, duration, and sham control. The quantity and quality of RCTs are lower so that we still have to boost the research level through scientific design and normative report.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Duan, Yuntao, Weijian Liang, Junming Hou, and Dezhen Yang. "Research Progress on the Antitumor Mechanism of Compound Kushen Injection." Proceedings of Anticancer Research 5, no. 5 (September 24, 2021): 4–6. http://dx.doi.org/10.26689/par.v5i5.2511.

Повний текст джерела

Анотація:

Compound Kushen Injection (CKI), as a clinical traditional Chinese medicine preparation, has prominent antitumor effect but with several side effects. A large number of studies have shown that CKI plays an antitumor role by regulating tumor cell proliferation, inducing tumor cell differentiation and apoptosis, inhibiting tumor cell invasion and metastasis, reducing tumor angiogenesis, regulating the immunity, and so on. Clinically, CKI is widely used to treat various tumors, where it is often combined with surgery, chemotherapy, radiotherapy, targeted therapy, and other antitumor treatments. This article reviews the antitumor mechanism of CKI and the progress of its clinical application in order to provide a theoretical basis for further clinical application.

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Wang, Wei, Rong-li You, Wen-jie Qin, Li-na Hai, Ming-jing Fang, Guo-hua Huang, Rui-xia Kang, et al. "Anti-tumor activities of active ingredients in Compound Kushen Injection." Acta Pharmacologica Sinica 36, no. 6 (May 18, 2015): 676–79. http://dx.doi.org/10.1038/aps.2015.24.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Meng, Ziqi, Xinkui Liu, Jiarui Wu, Wei Zhou, Kaihuan Wang, Zhiwei Jing, Shuyu Liu, Mengwei Ni, and Xiaomeng Zhang. "Mechanisms of Compound Kushen Injection for the Treatment of Lung Cancer Based on Network Pharmacology." Evidence-Based Complementary and Alternative Medicine 2019 (May 28, 2019): 1–15. http://dx.doi.org/10.1155/2019/4637839.

Повний текст джерела

Анотація:

Background. Compound Kushen Injection (CKI) is a Chinese patent drug that shows good efficacy in treating lung cancer (LC). However, its underlying mechanisms need to be further clarified.Methods. In this study, we adopted a network pharmacology method to gather compounds, predict targets, construct networks, and analyze biological functions and pathways. Moreover, molecular docking simulation was employed to assess the binding potential of selected target-compound pairs.Results. Four networks were established, including the compound-putative target network, protein-protein interaction (PPI) network of LC targets, compound-LC target network, and herb-compound-target-pathway network. Network analysis showed that 8 targets (CHRNA3, DRD2, PRKCA, CDK1, CDK2, CHRNA5, MMP1, and MMP9) may be the therapeutic targets of CKI in LC. In addition, molecular docking simulation indicated that CHRNA3, DRD2, PRKCA, CDK1, CDK2, MMP1, and MMP9 had good binding activity with the corresponding compounds. Furthermore, enrichment analysis indicated that CKI might exert a therapeutic role in LC by regulating some important pathways, namely, pathways in cancer, proteoglycans in cancer, PI3K-Akt signaling pathway, non-small-cell lung cancer, and small cell lung cancer.Conclusions. This study validated and predicted the mechanism of CKI in treating LC. Additionally, this study provides a good foundation for further experimental studies and promotes the reasonable application of CKI in the clinical treatment of LC.

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Yang, Yang, Yu Lu, Tianduo Pei, Bao Guo, Jingquan Li, Hui Wang, and Qian Ba. "Compound kushen injection in cancer treatments: Efficacy, active ingredients, and mechanisms." Pharmacological Research - Modern Chinese Medicine 3 (June 2022): 100108. http://dx.doi.org/10.1016/j.prmcm.2022.100108.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Jiang, Hongqiang, Honglei Tu, Yanxia Jin, Xianjin Wu, Ziyi Luo, Yanling Chen, Dongdong Zhang, et al. "Therapeutic Effect of a Traditional Chinese Medicine Compound Mixture Compound Kushen Injection in Treating Multiple Myeloma." Blood 136, Supplement 1 (November 5, 2020): 31–32. http://dx.doi.org/10.1182/blood-2020-141929.

Повний текст джерела

Анотація:

Abstract Background: Multiple myeloma (MM) is a hematology malignant disease originated from B-cell line and still incurable. Compound Kushen Injection (CKI) as a Traditional Chinese Medicines are promising agents in our previous research for treating cancer. The effect of CKI on multiple myeloma was still unknown. Methods: In vitro experiment, flow cytometry was used to evaluate effect of CKI on multiple myeloma cells. Optofluidic chip was applied to detect effect at single-cell level. And in vivo RPMI-8226 GFP+ B-NSG mouse model was built to assess the role of CKI in multiple myeloma treatment. Results: CKI inhibited MM cells proliferation of and increased its apoptosis rate. And the cell cycle of MM cells was also arrested by CKI treatment. In contrast, CKI has few toxic effects on mesenchymal stem cells (MSCs) and MC3T3 cells. At the single-cell level, MM cells was died in time and dose dependent manner. Transcriptome find that the expression of MYC and TERT in CKI-treated RPMI-8226 cells was significantly down-regulated and confirmed by qRT-PCR and Western blot. Overexpression of TERT can partly reverse the inhibition effect of CKI on RPMI-8226 cells. B-NSG mouse was injected with GFP+ RPMI-8226 cells through caudal vein, and the disease was partially alleviated by decreased tumor burden in the CKI-treated group. Furthermore, it is surprising that in animal models with myeloma bone disease, the bone mass was higher in CKI treatment group than control. Conclusions: CKI inhibits MM cells through the MYC/TERT signaling pathway and improve the quality of life of MM mouse. Our findings provide preclinical evidence to show that CKI could be a promising candidate in human MM therapy. Disclosures No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Liang, Sixian, Yin Li, Xiangguo Zhang, Yugan Guo, and Suming Pan. "Molecular Evidence of Compound Kushen Injection Against Lung Cancer: A Network Pharmacology-Based Investigation from Western Medicine to Traditional Medicine." Anti-Cancer Agents in Medicinal Chemistry 21, no. 15 (September 8, 2021): 2012–22. http://dx.doi.org/10.2174/1871520621666210126090632.

Повний текст джерела

Анотація:

Background: Compound Kushen Injection (CKI) is used clinically for relieving cancer pain and treating various solid tumors, particularly lung cancer. However, the underlying mechanisms of CKI in lung cancer remain to be further elucidated. Objective: This study aimed to obtain evidence regarding the potential efficacy of the active compounds and therapeutic targets of CKI at a molecular level by using Network Pharmacology (NP), which is an emerging technique for dealing with complex systems, such as those of herbal medicine. Methods: The chemical and predicted target information of CKI was obtained from databases and computational prediction, respectively; lung-cancer drugs and their corresponding targets were retrieved from Drugbank and Drugcentral. The online tool, STRING, was used to gather target–pathway interactions for establishing a target–(pathway)–target network to identify the target group that was most relevant to cancer. Based on this module, a protein-protein interaction network was established for identifying the potential therapeutic targets and the potential active ingredients. Results: CKI might affect lung cancer drug targets or their neighbor nodes to trigger anti-cancer effects. The compounds that were predicted to bind to the potential therapeutic targets were recommended as potential active ingredients of CKI, which included naringenin from Baituling, and kurarinone and isoxanthohumol from Kushen. Conclusion: This NP-based study might provide insights into understanding CKI from the perspective of modern science with reference to approved Western medicine for lung cancer. Moreover, network-based methods could also be further used with distinct advantages in dealing with complex information and systems of medicine.

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Qu, Zhipeng, Jian Cui, Yuka Harata-Lee, Thazin Nwe Aung, Qianjin Feng, Joy M. Raison, Robert Daniel Kortschak, and David L. Adelson. "Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics." Oncotarget 7, no. 40 (September 1, 2016): 66003–19. http://dx.doi.org/10.18632/oncotarget.11788.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Liu, Shuyu, Xiaohong Hu, Xiaotian Fan, Ruiqi Jin, Wenqian Yang, Yifei Geng, and Jiarui Wu. "A Bioinformatics Research on Novel Mechanism of Compound Kushen Injection for Treating Breast Cancer by Network Pharmacology and Molecular Docking Verification." Evidence-Based Complementary and Alternative Medicine 2020 (August 11, 2020): 1–14. http://dx.doi.org/10.1155/2020/2758640.

Повний текст джерела

Анотація:

Compound Kushen injection (CKI) has been extensively used in treating breast cancer (BC). However, the molecular mechanism remains unclear. In this study, 16 active compounds of CKI were obtained from 3 articles for target prediction. Then, a compound-predicted target network and a compound-BC target network were conducted by Cytoscape 3.6.1. The gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the DAVID database. The binding energy between the key targets of CKI and the active compounds was studied by molecular docking. As a result, 16 active compounds of CKI were identified, corresponding to 285 putative targets. The key targets of CKI for BC are HSD11B1, DPP4, MMP9, CDK1, MMP2, PTGS2, and CA14. The function enrichment analysis obtained 13 GO entries and 6 KEGG pathways, including bladder cancer, cancer pathways, chemical carcinogenesis, estrogen signaling pathway, TNF signaling pathway, and leukocyte transendothelial migration. The result of molecular docking indicated that DPP4 had strong binding activity with matrine, alicyclic protein, and sophoridine, and MMP9 had strong binding activity with adenine and sophoridine. In conclusion, the therapeutic effect of CKI on BC is based on the overall pharmacological effect formed by the combined effects of multiple components, multiple targets, and multiple pathways. This study provides a theoretical basis for further experimental research in the future.

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Dou, Dou, Ze-yu Zhang, Zhi-yuan Wu, Xu-dong Qiu, and Xiang-gen Zhong. "Aidi Injection, Compound Kushen Injection, or Kanglaite Injection: Which Is the Best Partner with Systemic Chemotherapy for Patients with HCC? A Network Meta-Analysis." Evidence-Based Complementary and Alternative Medicine 2020 (August 21, 2020): 1–11. http://dx.doi.org/10.1155/2020/5497041.

Повний текст джерела

Анотація:

Objective. The aim of this network meta-analysis (NMA) was to explore the effectiveness of different traditional Chinese medicine injections (TCMIs) combined with systemic chemotherapy for the treatment of hepatocellular carcinoma (HCC). Methods. A comprehensive search for randomized controlled trials (RCTs) was performed with regard to different TCMIs for treating HCC in seven electronic databases up to November 2019. The quality assessment of the included RCTs was conducted according to the Cochrane risk of bias tool. The objective response rate (ORR), clinical benefit rate (CBR), and Karnofsky performance score (KPS) data were extracted. The network meta-analysis used the network package in Stata software to analyse the data and draw a map of the evidence summarizing the direct and indirect comparisons. Results. A total of 1697 articles were retrieved through the comprehensive search. Twenty RCTs focusing on Aidi injection, compound Kushen injection, and Kanglaite injection as adjuvant therapies to chemotherapy were included, involving a total of 1418 patients. The NMA statistics showed that all three indicators (ORR, CBR, and KPS) were better in the combined treatment group of TCMIs with chemotherapy than that in the single treatment group of chemotherapy alone. Kanglaite injection tended to be better than the other two in terms of primary outcome, but there was not a significant difference. The combined treatment group had fewer adverse reactions than the single treatment group. Moreover, several articles reported that TCMIs combined with chemotherapy could increase the number of CD3+ and CD4+ T lymphocytes and the ratio of CD4+/CD8+ T lymphocytes. Conclusions. TCMIs combined with systemic chemotherapy could be an effective and safe treatment option for patients with HCC. Kanglaite injection showed a tendency to be better than the other two kinds of injections in terms of ORR. Nevertheless, additional results from multicentre trials and high-quality studies will be pivotal for supporting our findings.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Cui, Jian, Zhipeng Qu, Yuka Harata-Lee, Hanyuan Shen, Thazin Nwe Aung, Wei Wang, R. Daniel Kortschak, and David L. Adelson. "The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms." PLOS ONE 15, no. 7 (July 30, 2020): e0236395. http://dx.doi.org/10.1371/journal.pone.0236395.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Ao, Man, Xu Xiao, and Qingshan Li. "Efficacy and safety of compound Kushen injection combined with chemotherapy on postoperative Patients with breast cancer." Medicine 98, no. 3 (January 2019): e14024. http://dx.doi.org/10.1097/md.0000000000014024.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Chen, Hongwei, Xiaojun Yao, Ting Li, Christopher Wai-Kei Lam, Huixia Zhang, Jue Wang, Wei Zhang, Elaine Lai-Han Leung, and Qibiao Wu. "Compound Kushen injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer." Medicine 98, no. 52 (December 2019): e18552. http://dx.doi.org/10.1097/md.0000000000018552.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Guo, Lizhong, Shanshan Wang, Xiaobo Lian, Miaomiao Sun, and Lei Luo. "Efficacy of compound kushen injection plus radiotherapy on nonsmall-cell lungcancer: A systematic review and meta-analysis." Journal of Cancer Research and Therapeutics 12, no. 4 (2016): 1298. http://dx.doi.org/10.4103/0973-1482.199538.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Yang, Yang, Mayu Sun, Wenbo Yao, Feng Wang, Xiaoguang Li, Wei Wang, Jingquan Li, et al. "Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib." Journal for ImmunoTherapy of Cancer 8, no. 1 (March 2020): e000317. http://dx.doi.org/10.1136/jitc-2019-000317.

Повний текст джерела

Анотація:

BackgroundThere is an urgent need for effective treatments for hepatocellular carcinoma (HCC). Immunotherapy is promising especially when combined with traditional therapies. This study aimed to investigate the immunomodulatory function of an approved Chinese medicine formula, compound kushen injection (CKI), and its anti-HCC efficiency in combination with low-dose sorafenib.MethodsGrowth of two murine HCC cells was evaluated in an orthotopic model, a subcutaneous model, two postsurgical recurrence model, and a tumor rechallenge model with CKI and low-dose sorafenib combination treatment. In vivo macrophage or CD8+T cell depletion and in vitro primary cell coculture models were used to determine the regulation of CKI on macrophages and CD8+T cells.ResultsCKI significantly enhanced the anticancer activity of sorafenib at a subclinical dose with no obvious side effects. CKI and sorafenib combination treatment prevented the postsurgical recurrence and rechallenged tumor growth. Further, we showed that CKI activated proinflammatory responses and relieved immunosuppression of tumor-associated macrophages in the HCC microenvironment by triggering tumor necrosis factor receptor superfamily member 1 (TNFR1)-mediated NF-κB and p38 MAPK signaling cascades. CKI-primed macrophages significantly promoted the proliferation and the cytotoxic ability of CD8+T cells and decreased the exhaustion, which subsequently resulted in apoptosis of HCC cells.ConclusionsCKI acts on macrophages and CD8+T cells to reshape the immune microenvironment of HCC, which improves the therapeutic outcomes of low-dose sorafenib and avoids adverse chemotherapy effects. Our study shows that traditional Chinese medicines with immunomodulatory properties can potentiate chemotherapeutic drugs and provide a promising approach for HCC treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Jin, Yanxia, Qian Yang, Li Liang, Lu Ding, Yuxing Liang, Dongdong Zhang, Tian Yang, Mingfeng Zhao, and Fuling Zhou. "A Potential Mechanism for the Antioxidant Compound Kushen Injection Targeting the ROS Signaling Pathway in Acute Myeloid Leukemia." Blood 132, Supplement 1 (November 29, 2018): 5221. http://dx.doi.org/10.1182/blood-2018-99-114066.

Повний текст джерела

Анотація:

Abstract Abstract It is a challenge for treatment of acute myeloid leukemia (AML) in clinic. The increase in the levels of reactive oxygen species (ROS) in AML patients has been previously described; thus, it is important to regulate ROS levels in AML. In this study, we found that intracellular ROS levels in AML cells were decreased, the total antioxidant capacity (T-AOC) and glutathione (GSH) contents were increased and xanthine oxidase (XOD) vitality was decreased when treated with the compound kushen injection (CKI). This shows that CKI inhibited the proliferation of AML cell lines and patient cells and enhanced the cytotoxicity of AML cells, which has few toxic effects on haematopoietic stem cells (HSCs) and T cells. At the single-cell level, individual AML cells died gradually by CKI treatment on optofluidic chips. CKI could promote apoptosis and arrest cell cycle at G1/G0 phase in U937 cells. Furthermore, higher peroxiredoxin-3 (Prdx3) expression levels were found in CKI-treated U937 cells through quantitative proteomics detection. Mechanically, the expression of Prdx3 and peroxiredoxin-2 (Prdx2) was up-regulated in CKI-treated AML cells, while thioredoxin 1 (Trx1) was reduced. Laser confocal microscopy showed that the Prdx2 and Trx1 proteins could be co-localized by CKI treatment. In vivo, in the CKI-treated group, survival was longer in an AML patient-derived xenograft model in B-NSG mice. The disease was partially alleviated by decreased CD45+ immunophenotyping in peripheral blood and bone marrow smear analysis. After CKI injection, the T-AOC vitality, GSH content and CAT activity increased and the concentration of H2O2decreased in mouse plasma. A bone marrow biopsy and immunohistochemistry analysis showed that Prdx3 and Prdx2 expression was increased, while Trx1 expression was decreased. In a conclusion, we provided a model for the anti-leukaemic effects of CKI. CKI decreased intracellular ROS levels by up-regulating the expression of Prdx2 in the cytoplasm and Prdx3 in the mitochondria and down-regulating Trx1 expression, which maintained the intracellular REDOX and further inhibited AML cell proliferation. Therefore, antioxidant CKI is a promising drug for the treatment of AML in the clinic. We aimed to explore the therapeutic efficacy of low toxicity natural antioxidants against AML by targeting ROS pathways and providing new strategies to improve survival in AML patients. Disclosures No relevant conflicts of interest to declare.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Shao, Q. "987 poster THE RECENT EFFECT OF RADIOTHERAPY COMBINED WITH COMPOUND KUSHEN INJECTION FOR ELDERLY PATIENTS WITH ESOPHAGEAL CANCER." Radiotherapy and Oncology 99 (May 2011): S372—S373. http://dx.doi.org/10.1016/s0167-8140(11)71109-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Zhang, Jingyun, Caijian Li, Chengwei Fu, Jinkai Dong, Wei Guo, and Qianqian Zhu. "Effect of Psychological Intervention Combined with Family Cooperation on the Perioperative Quality of Life and Psychological States of Elderly Patients with Prostate Cancer Treated with Compound Kushen Injection." Evidence-Based Complementary and Alternative Medicine 2021 (July 19, 2021): 1–7. http://dx.doi.org/10.1155/2021/2971644.

Повний текст джерела

Анотація:

Objective. The purpose of the study was to investigate the nursing effect of psychological intervention combined with family cooperation on elderly patients with prostate cancer treated with compound kushen injection and put forward effective suggestions. Methods. 122 elderly patients with prostate cancer admitted to our hospital from June 2018 to June 2019 were selected and randomly divided into a control group (n = 61) and experimental group (n = 61). The patients in the control group received routine nursing intervention during the perioperative period, while the patients in the experimental group were treated with psychological intervention combined with family cooperation on the basis of routine nursing. The quality of life and psychological states of patients in the two groups were statistically analyzed. Results. The evaluation of psychological states at 24 hours before surgery and 24 hours before discharge in the experimental group was significantly better than that in the control group ( P < 0.05 ), with statistical significance. On comparing the basic conditions between the two groups in the perioperative period, the length of hospitalization, length of catheter retention after surgery, and incidence of complications in the experimental group were all significantly better than those in the control group ( P < 0.05 ), with statistical significance. The satisfaction of patients with the nursing process in both groups was recorded and statistically analyzed through questionnaires. The satisfaction with nursing process in the experimental group was significantly higher than that in the control group ( P < 0.05 ), with statistical significance. The quality of life of the patients was followed up at three months after discharge. The quality of life of the experimental group was significantly better than that of the control group ( P < 0.05 ), with statistical significance. Conclusion. Psychological intervention combined with family cooperation for the elderly patients with prostate cancer treated with compound kushen injection is beneficial to improve their psychological states, encourage them to face the disease in a more positive manner, effectively improve the quality of life after intervention, ensure the therapeutic effect during perioperative period, increase happiness index, and enhance their satisfaction with the nursing process, which is worthy of clinical application and popularization.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Tu, Honglei, Bo Lei, Shan Meng, Hailing Liu, Yongchang Wei, Aili He, Wanggang Zhang, and Fuling Zhou. "Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia." Evidence-Based Complementary and Alternative Medicine 2016 (2016): 1–7. http://dx.doi.org/10.1155/2016/3121402.

Повний текст джерела

Анотація:

We assessed the clinical effectiveness and safety of CKI (compound Kushen injection) plus standard induction chemotherapy for treating adult acute leukemia (AL). We randomly assigned 332 patients with newly diagnosed AL to control (n= 165, receiving DA (daunorubicin and cytarabine) or hyper-CVAD (fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone)) or treatment (n= 167, receiving CKI and DA or hyper-CVAD) groups. Posttreatment, treatment group CD3+, CD4+, CD4+/CD8+, natural killer (NK) cell, and immunoglobulin (IgG, IgA, and IgM) levels were significantly higher than those of the control group (p< 0.05), and CD8+ levels were lower in the treatment group than in the control group (p< 0.05). Treatment group interleukin- (IL-) 4 and IL-10 levels were significantly higher compared to the control posttreatment (bothp< 0.05) as were complete remission, overall response, and quality of life (QoL) improvement rates (p< 0.05). The control group had more incidences of grade 3/4 hematologic and nonhematologic toxicity (p< 0.05). Responses to induction chemotherapy, QoL improvement, and adverse events incidence between control group patients with acute myeloid leukemia and acute lymphocytic leukemia were not significantly different. CKI plus standard induction chemotherapy is effective and safe for treating AL, possibly by increasing immunologic function.

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Wang, Ke-xin, Yu-peng Chen, Ai-ping Lu, Guan-hua Du, Xue-mei Qin, Dao-gang Guan, and Li Gao. "A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC." Journal of Ethnopharmacology 274 (June 2021): 114043. http://dx.doi.org/10.1016/j.jep.2021.114043.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Wu, Xingkang, Chenchen Han, Lu Wang, and Xuemei Qin. "Iron increases the susceptibility of colorectal cancer cells to compound Kushen Injection via the decrease of TOP2A and p53." Pharmacological Research - Modern Chinese Medicine 2 (March 2022): 100058. http://dx.doi.org/10.1016/j.prmcm.2022.100058.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Xu, Weiru, Hongsheng Lin, Ying Zhang, Xinyi Chen, Baojin Hua, Wei Hou, Xin Qi та ін. "Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/β-catenin pathway". Journal of Experimental & Clinical Cancer Research 30, № 1 (2011): 103. http://dx.doi.org/10.1186/1756-9966-30-103.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Yu, Lixiu, Ying Zhou, Yu Yang, Furong Lu, and Yeqin Fan. "Efficacy and Safety of Compound Kushen Injection on Patients with Advanced Colon Cancer: A Meta-Analysis of Randomized Controlled Trials." Evidence-Based Complementary and Alternative Medicine 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/7102514.

Повний текст джерела

Анотація:

Objective. The efficacy and safety of Compound Kushen Injection (CKI) on advanced colon cancer remain controversial. We undertook a systematic meta-analysis of randomized controlled clinical studies on this issue.Methods. A comprehensive literature search was conducted by searching the following electronic databases: PubMed, Cochrane, Chinese Biological Medical disc, Chinese National Knowledge Infrastructure, and Wan-Fang Database in China by the end of January 31, 2017, without language restriction. Meta-analysis was performed by using the random effects model to estimate the summary odd ratio (OR) with 95% confidence interval (CI) according to the study design. Stata 12.0 software was used for data analysis. The heterogeneity, sensitivity, and publication bias were assessed, respectively.Results. A total of 14 trials met the inclusion criteria in present meta-analysis. The results suggested that CKI combined with chemotherapeutic drugs was favorable for the treatment of advanced colon cancer and could improve the patients’ life quality. Funnel plot analysis and Egger’s test suggested that there was not significant publication bias, and the sensitivity analysis indicated stable results.Conclusion. The current evidence suggested that CKI is favorable to improve the efficacy of chemotherapeutic drugs in patients with advanced colon cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Liang, QI, ZHANG Jing, and ZHANG Zhiqi. "Determination of four alkaloids in Compound Kushen Injection by high performance liquid chromatography with ionic liquid as mobile phase additive." Chinese Journal of Chromatography 31, no. 3 (2013): 249–53. http://dx.doi.org/10.3724/sp.j.1123.2012.10039.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Zhang, Wuguang, Wenqian Gong, Xiansong He, Changhai Wu, and Xiaolong Tu. "A systematic review and meta-analysis on the efficacy of Compound Kushen Injection in 3 kinds of digestive tract tumor." Journal of Gastrointestinal Oncology 12, no. 6 (December 2021): 2919–29. http://dx.doi.org/10.21037/jgo-21-774.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

ZHANG, Li-Hui, Wan-Ying ZHANG, Jia-Ming XIONG, Xiu-Mei DUAN, Li-Na HAI, Yu-Liang ZHANG, Miao-Miao ZHANG, Gui-Fang QIN, and Guo-Wei ZHANG. "Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation." Chinese Journal of Natural Medicines 20, no. 1 (January 2022): 43–53. http://dx.doi.org/10.1016/s1875-5364(22)60144-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Yanju, Bao, Liping Yang, Baojin Hua, Wei Hou, Zhan Shi, Weidong Li, Conghuang Li, et al. "A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain." Supportive Care in Cancer 22, no. 3 (November 26, 2013): 825–36. http://dx.doi.org/10.1007/s00520-013-2063-5.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Zhang, WanYing, Ying Chen, MiaoMiao Zhang, and GuoWei Zhang. "Molecular mechanism prediction analysis of compound Kushen injection in the treatment of COVID-19 based on network pharmacology and molecular docking." Traditional Medicine Research 5, no. 5 (2020): 413–24. http://dx.doi.org/10.53388/tmr20200518180.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Ma, Yue, Huimin Gao, Jing Liu, Liangmian Chen, Qiwei Zhang, and Zhimin Wang. "IDENTIFICATION AND DETERMINATION OF THE CHEMICAL CONSTITUENTS IN A HERBAL PREPARATION, COMPOUND KUSHEN INJECTION, BY HPLC AND LC-DAD-MS/MS." Journal of Liquid Chromatography & Related Technologies 37, no. 2 (October 23, 2013): 207–20. http://dx.doi.org/10.1080/10826076.2012.738623.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Pu, Liu, Wei-hao Chen, Lu-xi Cao, Kun-ji Wu, Shu-lian Chen, Ji-huan Lin, Cheng-lu Li, Shi-qi Wang, Ming-min Zhu, and Yi-min Zhang. "Compound Kushen Injection as an Adjunctive Therapy for the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials." Evidence-Based Complementary and Alternative Medicine 2019 (November 6, 2019): 1–11. http://dx.doi.org/10.1155/2019/7241927.

Повний текст джерела

Анотація:

Objectives. To evaluate the efficacy and safety of compound Kushen injection (CKI) combined with chemo treatment (chemo) for non-small-cell lung cancer (NSCLC). Methods. We systematically searched the literature published in seven databases, including Embase, PubMed, central, MEDLINE, CNKI, Wanfang, and VIP, from their inception to April 2019 for all randomized controlled trials (RCTs) comparing CKI plus chemo with chemo alone in patients with NSCLC. Our main end point was clinical efficiency and the secondary outcomes were Karnofsky performance score (KPS), immune function, and adverse events. The Cochrane risk of bias tool was applied for quality assessment. Results. 10 studies involving 1019 participants were included. The clinical response rate (relative risk (RR) = 1.21, 95% confidence interval (CI): 1.06 to 1.37; P=0.003), KPS (RR = 2.18, 95% CI: 1.49 to 3.17; P<0.0001), immune function (mean differences (MD) = 0.82, 95% CI: 0.12 to 1.52; P=0.02) and adverse effects (RR = 0.67, 95% CI: 0.60 to 0.74; P<0.00001) in the CKI plus chemo group showed significant differences when compared with chemo alone. Conclusions. CKI combined with chemo can improve clinical efficiency, KPS, and immune function and reduce adverse reactions in patients with NSCLC when compared with chemo alone. However, more rigorously designed RCTs are needed to validate this benefit, as some of the included RCTs are of low methodological quality.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Yu, Ze-Yu, Rong-Yan Peng, Mei Han, Suzanne Grant, Guo-Yan Yang, Jian-Ping Liu, and Hui-Juan Cao. "Adjunctive effect of compound Kushen Injection to chemotherapy for non-small cell lung cancer: An evidence map and overview of systematic reviews." Journal of Ethnopharmacology 281 (December 2021): 114538. http://dx.doi.org/10.1016/j.jep.2021.114538.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Wu, Xingkang, Yufang Lu, and Xuemei Qin. "Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis." Journal of Ethnopharmacology 283 (January 2022): 114690. http://dx.doi.org/10.1016/j.jep.2021.114690.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Chen, Zhi-Ying, Yue Liu, Yuan Wei, Lin-Yao Deng, and Qiang Zhang. "Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients." Evidence-Based Complementary and Alternative Medicine 2022 (July 22, 2022): 1–22. http://dx.doi.org/10.1155/2022/6875253.

Повний текст джерела

Анотація:

Background. Oxaliplatin is an effective chemotherapeutic agent for the treatment of malignant tumors. However, severe oxaliplatin-induced peripheral neurotoxicity (OIPN) has been well documented. Traditional Chinese medicine injections (TCMIs) have shown significant efficacy in preventing OIPN. However, it is difficult for clinicians to determine the differences in the efficacy of various TCMIs in preventing OIPN. The aim of this study was to compare the efficacy of various TCMIs in preventing OIPN through a network meta-analysis (NMA) to further inform clinical decision-making. Methods. The Chinese Journal Full Text Database, Chinese Biomedical Literature Database, Wanfang Data Knowledge Service Platform, Chinese Science and Technology Journal Full Text Database, the Cochrane Library, Web of Science, PubMed, and Embase databases were searched for randomized controlled trials (RCTs) of TCMIs for OIPN prevention. The retrieval time was from the establishment of the database to April 12, 2021. NMA was performed using Stata 14.0 software after 2 evaluators independently screened the literature, extracted information, and evaluated the risk of bias of the included studies. Results. A total of 45 eligible RCTs involving 3598 cancer patients and 13 TCMIs were included. The 13 TCMIs included Xiaoaiping injection (XAPI), compound kushen injection (CKSI), Aidi injection (ADI), Brucea javanica oil emulsion injection (BJOEI), Shenmai injection (SMI), Kangai injection (KAI), Astragalus injection (AI), elemene emulsion injection (EEI), Shenfu injection (SFI), Shenqi Fuzheng injection (SIFZI), Kanglaite injection (KLEI), Huachansu injection (HCSI), and lentinan injection (LI). NMA results showed that AI was superior to AD and SIFZI was superior to ADI in reducing the incidence of grade I neurotoxicity. SIFZI was superior to EEI and ADI, and BJOEI was superior to chemotherapy alone in reducing the incidence of grade II neurotoxicity. SMI was superior to LI and CKSI in reducing the incidence of grade III neurotoxicity. SIFZI was superior to LI, BJOEI, XAPI, EEI, SMI, chemotherapy alone, HCSI, KLEI, and ADI in reducing the total incidence of grade I–IV neurotoxicity. SFI was superior to ADI. Based on the SUCRA values, AI was the most likely intervention to reduce the incidence of grade I neurotoxicity, SIFZI was the most likely intervention to reduce the total incidence of grade II and I–IV neurotoxicity, and SMI was the most likely intervention to reduce the incidence of grade III and IV neurotoxicity. Conclusion. TCMIs can prevent OIPN to some extent, among which SIFZI, SMI, and AI may be the most promising TCMIs. However, given the limitations of current studies, more well-designed, high-quality clinical trials will be needed in the future to validate the benefits of TCMIs.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Yang, Huisheng, Yanming Xie, Jisheng Ni, Yue Liu, Rui Song, Cen Chen, Yan Zhuang, and Yin Zhang. "Association Rule Analysis for Validating Interrelationships of Combined Medication of Compound Kushen Injection in Treating Colon Carcinoma: A Hospital Information System-Based Real-World Study." Evidence-Based Complementary and Alternative Medicine 2018 (August 30, 2018): 1–10. http://dx.doi.org/10.1155/2018/4579801.

Повний текст джерела

Анотація:

Background. Real world evidence is important for informing healthcare practice and developing medical products and has gained broad interest in healthcare. Compound Kushen Injection (CKI) has been widely applied into treatment of colon carcinoma (CC) in China. Postapproval drug assessment related retrospective studies using electrical medical record (EMR) collected from hospital information system (HIS) is one of the most important categories of real-world study (RWS). Based on HIS EMR, interrelationships of combined medication of CKI in treating CC can be validated in real world settings. Methods. This study was conducted based on a large-scale integrated database of EMR derived from HIS. EMR of 3328 patients initially diagnosed with CC among 49,597 patients treated with CKI were included in the study. Descriptive statistical analyses and apriori algorithm based association rule analyses were performed, respectively, to validate frequency distribution and interrelationships of combined medication of CKI in treating CC. Results. The pharmacological mechanisms of TCMs that have been commonly used in conjunction with CKI include heat-clearing and detoxifying, qi-reinforcing, blood circulation-promoting and stasis-removing, blood-stanching, and qi-regulating. For modern medicines, antibiotics, antineoplastic chemotherapeutic drugs, immunomodulator, 5-HT receptor antagonist drugs, and corticosteroids are most often combined with CKI. The association rules of medication combinations of CKI in treating CC in real world manifest certain laws for both TCMs and modern medicines. They are generally in line with CC treatment guidelines. Conclusions. It is a common practice for CKI to be integrated with both modern medicines and TCMs when treating CC in China. The associations of medication combinations of CKI in treating CC manifest certain laws for both TCMs and modern medicines. The RWS for validating interrelationships of combined medication may provide evidence for rational use of CKI. Further explorations are needed to verify and expand the conclusions.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Bao, Yanju, Xiangying Kong, Liping Yang, Rui Liu, Zhan Shi, Weidong Li, Baojin Hua, and Wei Hou. "Complementary and Alternative Medicine for Cancer Pain: An Overview of Systematic Reviews." Evidence-Based Complementary and Alternative Medicine 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/170396.

Повний текст джерела

Анотація:

Background and Objective. Now with more and more published systematic reviews of Complementary and Alternative Medicine (CAM) on adult cancer pain, it is necessary to use the methods of overview of systematic review to summarize available evidence, appraise the evidence level, and give suggestions to future research and practice.Methods. A comprehensive search (the Cochrane Library, PubMed, Embase, and ISI Web of Knowledge) was conducted to identify all systematic reviews or meta-analyses of CAM on adult cancer pain. And the evidence levels were evaluated using GRADE approach.Results. 27 systematic reviews were included. Based on available evidence, we could find that psychoeducational interventions, music interventions, acupuncture plus drug therapy, Chinese herbal medicine plus cancer therapy, compound kushen injection, reflexology, lycopene, TENS, qigong, cupping, cannabis, Reiki, homeopathy (Traumeel), and creative arts therapies might have beneficial effects on adult cancer pain. No benefits were found for acupuncture (versus drug therapy or shame acupuncture), and the results were inconsistent for massage therapy, transcutaneous electric nerve stimulation (TENS), andViscum albumL plus cancer treatment. However, the evidence levels for these interventions were low or moderate due to high risk of bias and/or small sample size of primary studies.Conclusion. CAM may be beneficial for alleviating cancer pain, but the evidence levels were found to be low or moderate. Future large and rigor randomized controlled studies are needed to confirm the benefits of CAM on adult cancer pain.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Lai, Bao-Yong, Ai-Jing Chu, Bo-Wen Yu, Li-Yan Jia, Ying-Yi Fan, Jian-Ping Liu, and Xiao-Hua Pei. "Clinical Effectiveness and Safety of Chinese Herbal Medicine Compound Kushen Injection as an Add-On Treatment for Breast Cancer: A Systematic Review and Meta-Analysis." Evidence-Based Complementary and Alternative Medicine 2022 (January 10, 2022): 1–16. http://dx.doi.org/10.1155/2022/8118408.

Повний текст джерела

Анотація:

Objective. To systematically evaluate the effect and safety of compound Kushen injection (CKI) as an add-on treatment on the treatment for breast cancer. Methods. We searched eight major electronic databases from their inception to November 1, 2021, for randomized clinical trials (RCTs) comparing CKI plus chemotherapy with chemotherapy alone. Primary outcomes included objective response rate (ORR) and disease control rate (DCR), health-related quality of life (HRQoL), progression-free survival (PFS), and overall survival (OS). Secondary outcomes included adverse drug reactions (ADRs) and tumor marker level. We used Cochrane’s RevMan 5.3 for data analysis. The GRADEpro was used to appraise the certainty of evidence. Trial sequential analysis (TSA) was applied to estimate the required sample size in a meta-analysis and test the robustness of the current results. Results. Thirty RCTs with 2556 participants were totally included. CKI plus chemotherapy showed significant effects in increasing ORR (RR 1.30, 95%CI [1.18, 1.43], I2 = 27%, n = 1694), increasing DCR (RR 1.21, 95%CI [1.15, 1.28], I2 = 16%, n = 1627), increasing HRQol as measured by Karnofsky Performance Scale (KPS) score improvement rate (RR 1.42, 95% CI [1.26, 1.61], I2 = 37%, n = 1172), increasing the PFS (MD 2.24 months, 95%CI [1.26, 3.22], n = 94) and the OS (MD 2.24 months, 95%CI [1.45, 3.43], n = 94), compared to chemotherapy alone. The results showed that CKI plus chemotherapy had a lower risk of ADRs than that of chemotherapy alone group. The certainty of evidence of the included trials was generally low to very low. TSA for ORR and KPS score improvement rate demonstrated that the current results reached a sufficient power regarding both numbers of trials and participants. Conclusions. Low certainty of evidence suggested that the combination of CKI and conventional chemotherapy appeared to improve ORR, DCR, and KPS score in breast cancer patients. Conclusions about PFS and OS could not be drawn due to lack of evidence. Additionally, CKI appeared to relieve the risk of ADRs in patients with breast cancer receiving chemotherapies. However, due to weak evidence, the findings should be further confirmed in large and rigorous trials.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Yu, Q., S. Yuan, and J. Wang. "A Multi-Center Randomized Trial Using Compound Kushen Injection to Decrease Chemoradiotherapy Induced Thoracic Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer." International Journal of Radiation Oncology*Biology*Physics 105, no. 1 (September 2019): E539—E540. http://dx.doi.org/10.1016/j.ijrobp.2019.06.2457.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Zhou, Wei, Zhihong Huang, Chao Wu, Shan Lu, Changgeng Fu, Peizhi Ye, Yingying Tan, et al. "Investigation on the clinical efficacy and mechanism of compound kushen injection in treating esophageal cancer based on multi-dimensional network meta-analysis and in vitro experiment." Journal of Ethnopharmacology 279 (October 2021): 114386. http://dx.doi.org/10.1016/j.jep.2021.114386.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Yang, Yang, Yanxia Ma, Zhanzheng Wang, Li Wang, Yubo Zhao, Yang Hui, Chi Zhang, and Feixue Feng. "Compound Kushen Injection Promoted the Killing Effect of Cytokine-Induced Killer Cells Which Was Activated by Dendritic-Colon Cancer Stem Cell Fusion Cells on Colon Cancer Stem Cells." Journal of Biomaterials and Tissue Engineering 10, no. 7 (July 1, 2020): 957–65. http://dx.doi.org/10.1166/jbt.2020.2362.

Повний текст джерела

Анотація:

Colon cancer stem cells (cCSCs) are highly tumorigenic and resistant to traditional chemotherapeutic drugs. Therefore, they are an essential factor in colorectal cancer (CRC) metastasis and recurrence. Dendritic cells (DCs) could bind to the tumor cells and form the fusion cells (FCs). And these FCs could inhibit the development of malignant tumors. Furthermore, the cytokine induced killer (CIK) cells (CD3+ /CD56+ T lymphocytes) could also apply for the immunotherapy of cancer. And compound Kushen injection (CKI) is a traditional Chinese medicine (TCM) which has been used for the treatment of various tumors. However, whether the dendritic-colon cancer stem cell fusion cells (DC-cCSC FCs) could activate the CIK cells and kill the colon cancer stem cells is unknown. And whether the CKI could enhance the lethal effect is still unclear. In this study, we collected peripheral blood samples from healthy participants to acquire mononuclear cells and induced DC and CIK cells. Meanwhile, the CD44+ cells (cCSCs) were screened from SW480 cells. Next, the DC-cCSC FCs were established for the next experiments. At last, CCK-8 assays were performed to determine the effect of DC-cCSC FCs and CKI on the viability of cCSCs. We found that DC-cCSC FCs enhanced the proliferation of CIK cells and induce the CIK cells to secrete more IL-12. The DC-cCSC FCs enhanced the inhibitory effect of CIK cells on cCSCs. Furthermore, application of CKI enhanced the killing rates of DC-cCSC FCs and CIK cells on cCSCs. CIK cells activated by the DC-cCSC FCs had the lethal effect on the cCSCs. Furthermore, CKI enhanced this lethal effect of DC-cCSC FCs and CIK cells.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Chen, Hongwei, Xiaojun Yao, Ting Li, Christopher Wai-Kei Lam, Ruonan Zhang, Huixia Zhang, Jue Wang, Wei Zhang, Elaine Lai-Han Leung, and Qibiao Wu. "Compound Kushen injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A meta-analysis of 37 RCTs following the PRISMA guidelines." Journal of Cancer 11, no. 7 (2020): 1883–98. http://dx.doi.org/10.7150/jca.40267.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Zhongquan, Zhao, Liao Hehe, and Ju Ying. "Effect of compound Kushen injection on T-cell subgroups and natural killer cells in patients with locally advanced non-small-cell lung cancer treated with concomitant radiochemotherapy." Journal of Traditional Chinese Medicine 36, no. 1 (February 2016): 14–18. http://dx.doi.org/10.1016/s0254-6272(16)30002-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Wu, Huan, Lina Wang, Xiang Zhan, Bin Wang, Jiawen Wu, and An Zhou. "A UPLC-Q-TOF/MS-based plasma metabolomics approach reveals the mechanism of Compound Kushen Injection-based intervention against non-small cell lung cancer in Lewis tumor-bearing mice." Phytomedicine 76 (September 2020): 153259. http://dx.doi.org/10.1016/j.phymed.2020.153259.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Cang, Song, Ran Liu, Tianyang Wang, Xiaoyan Jiang, Wenhua Zhang, Kaishun Bi, and Qing Li. "Simultaneous determination of five active alkaloids from Compound Kushen Injection in rat plasma by LC–MS/MS and its application to a comparative pharmacokinetic study in normal and NSCLC nude rats." Journal of Chromatography B 1126-1127 (September 2019): 121734. http://dx.doi.org/10.1016/j.jchromb.2019.121734.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Hou, Chao, Die Yang, Yusen Zhang, Yifei Li, Zhengfei He, Xiaojun Dai, Qingyun Lu, Shanshan Wang, Xiaochun Zhang, and Yanqing Liu. "Effect of Fuzheng Qingdu Therapy for Metastatic Gastric Cancer is Associated With Improved Survival: A Multicenter Propensity-Matched Study." Integrative Cancer Therapies 20 (January 2021): 153473542110584. http://dx.doi.org/10.1177/15347354211058464.

Повний текст джерела

Анотація:

Objective To evaluate the therapeutic effect of Traditional Chinese Medicine (TCM), specifically Fuzheng Qingdu (FZQD) therapy, on the survival time of metastatic GC patients. Patients and Methods Databases of medical records of 6 hospitals showed that 432 patients with stage IV GC were enrolled from March 1, 2012 to October 31, 2020. Propensity score matching (PSM) was used to reduce the bias caused by confounding factors in the comparison between the TCM and the non-TCM users. We used a Cox multivariate regression model to compare the hazard ratio (HR) value for mortality risk, and Kaplan-Meier survival curve for the survival time of GC patients Results The same number of subjects from the non-TCM group were matched with 122 TCM-treated patients after PSM to evaluate their overall survival (OS) and progression-free survival (PFS). Median time of OS of TCM and non-TCM users were 16.53 and 9.10 months, respectively. TCM and non-TCM groups demonstrated a 1-year survival rate of 68.5% and 34.5%, 2-year survival rate of 28.6% and 3.5%, and 3-year survival rate of 17.8% and 0.0%, respectively. A statistical difference exists in OS between the 2 groups (χ2 = 33.39 and P < .0001). The PFS of TCM users was also longer than that of non-TCM users (χ2 = 4.95 and P = 0.026). Notably, Chinese herbal decoction, Shenmai and compound Kushen injections were commonly used for FZQD therapy. Conclusion This propensity-matched study showed that FZQD therapy could improve the survival of metastatic GC patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Liu, Shuyu, Haojia Wang, Miaomiao Wang, Xiaohong Hu, Wenqian Yang, Ruiqi Jin, Yifei Geng, Mengwei Ni, Jiarui Wu, and Xiaomeng Zhang. "Comparative Efficacy and Safety of Chinese Herbal Injections Combined With Cyclophosphamide and 5-Fluorouracil Chemotherapies in Treatment of Breast Cancer: A Bayesian Network Meta-Analysis." Frontiers in Pharmacology 11 (January 27, 2021). http://dx.doi.org/10.3389/fphar.2020.572396.

Повний текст джерела

Анотація:

Background: Given the limitations of chemotherapy for the treatment of breast cancer (BC) and the wide exploration of Chinese herbal injections (CHIs), this network meta-analysis (NMA) was conducted to analyze the comparative efficacy and safety of nine CHIs combined with CF (Cyclophosphamide and 5-Fluorouracil) chemotherapy regimens in the treatment of BC.Methods: Several electronic databases were searched to identify randomized controlled trials (RCTs) from inception to January 6, 2020. RCTs were screened by pre-established eligibility criteria, and the quality of which was assessed using the Cochrane risk of bias tool. Outcomes such as the clinical effectiveness rate, performance status, peripheral hemogram, and detection of T-lymphocyte subsets were analyzed using the Winbugs 1.4.3 and Stata 13.0 software. Surface under the cumulative ranking curve (SUCRA) probability values were applied to rank the examined treatments. Cluster analysis was performed to compare the effect of CHIs between two or three different outcomes.Results: A total of 84 RCTs involving 7855 patients and nine CHIs were included. The results showed that compared to CF chemotherapy regimens alone, the ones injected along with Aidi, Shenmai, Shenqi Fuzheng, Kangai, Kanglaite, or Shengmai combined with CF can improve the clinical effectiveness rate. Aidi, Shenmai, Shenqi Fuzheng, Compound Kushen, Kangai, and Kanglaite injection combined with CF can improve the performance status. Shenqi Fuzheng injection was considered as a favorable choice for relieving adverse reactions. According to the results of cluster analysis, Aidi injection and Compound Kushen injection plus CF were more favorable for the clinical effectiveness rate and performance status.Conclusion: In conclusion, Shenqi Fuzheng, Compound Kushen, Aidi, and Kangai injection combined with CF chemotherapy regimen have more significant effects for patients with BC. However, more high-quality clinical RCTs, especialy which correctly use blinding and allocation concealment, are required to support the conclusions.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Yang, Ming, Si-jia Zhu, Chen Shen, Rui Zhai, Duo-duo Li, Min Fang, Jing-nan Xu, et al. "Clinical Application of Chinese Herbal Injection for Cancer Care: Evidence-Mapping of the Systematic Reviews, Meta-analyses, and Randomized Controlled Trials." Frontiers in Pharmacology 12 (May 7, 2021). http://dx.doi.org/10.3389/fphar.2021.666368.

Повний текст джерела

Анотація:

Background and objective: Cancer is a life-threatening disease worldwide and current standard therapy cannot fulfill all clinical needs. Chinese herbal injections have been widely used for cancer in Chinese and Western hospitals in China. This study aimed to apply evidence mapping in order to provide an overview of the clinical application of Chinese herbal injections in cancer care based on randomized controlled trials, systematic reviews, and meta-analyses.Methods and results: Seven databases were systematically searched for eligible randomized controlled trials, systematic reviews, and meta-analyses for ten Chinese herbal injections used in cancer treatment and covered in the Chinese national essential health insurance program. Excel 2016 and RStudio were used to integrate and process the data.In total 366 randomized controlled trials and 48 systematic reviews and meta-analyses were included in the evidence mapping of herbal medicines including; Compound Kushen, Shenqi Fuzheng, Aidi, Kangai, Kanglaite, Xiaoaiping, Cinobufacin, Brucea javanica oil emulsion, Polyporus polysaccharide injection, and Astragalus polysaccharide for injection. Health insurance restricts the scope of clinical application for these herbal injections. The numbers of studies published increased, especially around 2013–2015. The most studied cancer types were lung cancer (118, 32.2%), colorectal cancer (39, 10.7%), and gastric cancer (39, 10.7%), and the most used injections were Compound Kushen (78, 21.3%), Shenqi Fuzheng (76, 20.8%), and Aidi (63, 17.2%). The most consistently reported benefits were observed for Compound Kushen, Shenqi Fuzheng, Aidi, and Kangai for tumor response, quality of life, myelosuppression, and enhancing immunity.Conclusion: The current evidence mapping provides an overview of the outcomes and effects of Chinese herbal injections used in cancer care, and offers information on their clinical application which warrants further evidence-based research in order to inform clinical and policy decision-making.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Ni, Mengwei, Zhishan Wu, Haojia Wang, Wei Zhou, Chao Wu, Antony Stalin, Changgeng Fu, et al. "A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin." Frontiers in Pharmacology 12 (September 6, 2021). http://dx.doi.org/10.3389/fphar.2021.739673.

Повний текст джерела

Анотація:

Introduction: As non-small cell lung cancer (NSCLC) seriously threatens human health, several clinical studies have reported that Chinese herbal injections (CHIs) in combination with and gemcitabine plus cisplatin (GP) are beneficial. This multidimensional network meta-analysis aimed to compare the clinical efficacy and safety of different CHIs in combination with GP against NSCLC.Methods: Randomized controlled trials (RCTs) for the treatment of NSCLC were retrieved from seven electronic databases from inception to April 30, 2020. Study selection and data extraction were based on a priori criteria. Data analysis was performed using Stata 13.0, WinBUGS 14.0 software. Multidimensional cluster analysis was performed using the “scatterplot3d” package in R 3.6.1 software.Results: This network meta-analysis included 71 eligible RCTs and 10 Chinese herbal injections. Delisheng injection and Kangai injection had the highest probability in terms of clinical effectiveness rate (94.60%) and gastrointestinal reactions (82.62%) when combined with GP compared with the other interventions. Compound Kushen injection combined with GP ranked ahead of the other interventions in terms of performance status (73.36%) and abnormal liver function (87.17%). Shenmai injection combined with GP had the highest probability in terms of leukopenia (94.59%) and thrombocytopenia (99.18%).Conclusion: The current evidence revealed that CHIs combined with GP have a better impact on patients with NSCLC than GP alone. Aidi injection, Compound kushen injection, and Kanglaite injection deserve more attention of clinicians when combined with GP in patients with NSCLC. Additionally, due to the limitations of this network meta-analysis, further well-designed, large-sample, multicenter RCTs are required to support our findings adequately.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

He, Yutong, Dongli Guo, Jing Jin, Jianghui Liu, and Meng Ren. "Network Pharmacological Study of Compound Kushen Injection in Esophageal Cancer." Current Computer-Aided Drug Design 19 (January 11, 2023). http://dx.doi.org/10.2174/1573409919666230111155954.

Повний текст джерела

Анотація:

Aim: To provide new methods and ideas for the clinical application of integrated traditional Chinese and Western medicine in the treatment of esophageal cancer. Background: Traditional Chinese medicine compound Kushen injection (CKI) has been widely used in the clinic with adjuvant radiotherapy and chemotherapy. However, the mechanism of action of CKI as adjuvant therapy for esophageal cancer has not yet been described. Method: This study is based on network pharmacology, data mining, and molecular docking technology to explore the mechanism of action of CKI in the treatment of esophageal cancer. We obtained the effective ingredients and targets of CKI from the traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) and esophageal cancer-related genes from the Online Mendelian Inheritance in Man (OMIM) and GeneCards databases. Result: CKI mainly contains 58 active components. Among them, the top 5 active ingredients are quercetin, luteolin, naringenin, formononetin, and beta-sitostero. The target protein of the active ingredient was matched with the genes associated with esophageal cancer. The active ingredients targeted 187 esophageal cancer target proteins, including AKT1, MAPK1, MAPK3, TP53, HSP90AA1, and other proteins. Then, we enriched and analyzed the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) and used AutoDockVina to dock the core targets and compounds. Finally, PyMOL and Ligplot were used for data visualization. Conclusion: This study provides a new method and ideas for the clinical application of integrated traditional Chinese and Western medicine in the treatment of esophageal cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Compound Kushen Injection"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями